BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 10023310)

  • 1. High-dose chemotherapy in germ cell tumours: a large single centre experience.
    Rick O; Beyer J; Kingreen D; Schwella N; Krusch A; Schleicher J; Kirsch A; Huhn D; Siegert W
    Eur J Cancer; 1998 Nov; 34(12):1883-8. PubMed ID: 10023310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term survival of patients with recurrent or refractory germ cell tumors after high dose chemotherapy.
    Beyer J; Kingreen D; Krause M; Schleicher J; Schwaner I; Schwella N; Huhn D; Siegert W
    Cancer; 1997 Jan; 79(1):161-8. PubMed ID: 8988741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group.
    Siegert W; Beyer J; Strohscheer I; Baurmann H; Oettle H; Zingsem J; Zimmermann R; Bokemeyer C; Schmoll HJ; Huhn D
    J Clin Oncol; 1994 Jun; 12(6):1223-31. PubMed ID: 7911158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nephrotoxicity after high-dose carboplatin, etoposide and ifosfamide in germ-cell tumors: incidence and implications for hematologic recovery and clinical outcome.
    Beyer J; Rick O; Weinknecht S; Kingreen D; Lenz K; Siegert W
    Bone Marrow Transplant; 1997 Nov; 20(10):813-9. PubMed ID: 9404920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support.
    Margolin K; Doroshow JH; Ahn C; Hamasaki V; Leong L; Morgan R; Raschko J; Shibata S; Somlo G; Tetef M
    J Clin Oncol; 1996 Oct; 14(10):2631-7. PubMed ID: 8874321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [High dose chemotherapy with autologous stem cell support in the treatment of germ cell tumors: experience of the centre Léon-Bérard between 1982 and 1996].
    Fléchon A; Biron P; Philip I; Blay JY; Droz JP
    Bull Cancer; 1999 Apr; 86(4):391-9. PubMed ID: 10341344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial.
    Lorch A; Kleinhans A; Kramar A; Kollmannsberger CK; Hartmann JT; Bokemeyer C; Rick O; Beyer J
    J Clin Oncol; 2012 Mar; 30(8):800-5. PubMed ID: 22291076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-Dose Chemotherapy and Autologous Peripheral-Blood Stem-Cell Transplantation for Relapsed Metastatic Germ Cell Tumors: The Indiana University Experience.
    Adra N; Abonour R; Althouse SK; Albany C; Hanna NH; Einhorn LH
    J Clin Oncol; 2017 Apr; 35(10):1096-1102. PubMed ID: 27870561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group.
    Lorch A; Kollmannsberger C; Hartmann JT; Metzner B; Schmidt-Wolf IG; Berdel WE; Weissinger F; Schleicher J; Egerer G; Haas A; Schirren R; Beyer J; Bokemeyer C; Rick O;
    J Clin Oncol; 2007 Jul; 25(19):2778-84. PubMed ID: 17602082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcome of salvage high-dose chemotherapy in patients with germ cell tumor with poor prognostic features.
    De Giorgi U; Rosti G; Salvioni R; Papiani G; Ballardini M; Pizzocaro G; Marangolo M
    Urol Oncol; 2011; 29(3):284-90. PubMed ID: 19556152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose chemotherapy with hematopoietic stem-cell support in germ-cell tumor patient treatment: the French experience.
    Fléchon A; Biron P; Droz JP
    Int J Cancer; 1999 Dec; 83(6):844-7. PubMed ID: 10597208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is high-dose chemotherapy after primary chemotherapy a therapeutic option for patients with primary mediastinal nonseminomatous germ cell tumor?
    Banna GL; De Giorgi U; Ferrari B; Castagna L; Alloisio M; Marangolo M; Rosti G; Santoro A
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1085-91. PubMed ID: 17084372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage High-Dose Chemotherapy for Relapsed Pure Seminoma in the Last 10 Years: Results From the European Society for Blood and Marrow Transplantation Series 2002-2012.
    Necchi A; Lo Vullo S; Bregni M; Rosti G; Mariani L; Raggi D; Giannatempo P; Secondino S; Schumacher K; Massard C; Kanfer E; Oechsle K; Laszlo D; Michieli M; Ifrah N; Mercier M; Crysandt M; Wuchter P; Nagler A; Wahlin A; Martino M; Badoglio M; Pedrazzoli P; Lanza F;
    Clin Genitourin Cancer; 2017 Feb; 15(1):163-167. PubMed ID: 27444987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission.
    Rodenhuis S; de Wit R; de Mulder PH; Keizer HJ; Sleijfer DT; Lalisang RI; Bakker PJ; Mandjes I; Kooi M; de Vries EG
    Ann Oncol; 1999 Dec; 10(12):1467-73. PubMed ID: 10643538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose chemotherapy with autologous stem cell transplantation in relapsed or refractory germ cell tumours: outcomes and prognostic variables in a case series of 17 patients.
    Lewin J; Dickinson M; Voskoboynik M; Collins M; Ritchie D; Toner G
    Intern Med J; 2014 Aug; 44(8):771-8. PubMed ID: 24893627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stable hematopoietic recovery after peripheral blood stem cell transplantation in patients receiving high-dose chemotherapy for advanced germ cell tumors.
    Kumano M; Miyake H; Hara I; Furukawa J; Takenaka A; Fujisawa M
    Anticancer Res; 2006; 26(6C):4965-8. PubMed ID: 17214371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of irinotecan, paclitaxel, and oxaliplatin (IPO) in relapsed germ cell tumours with high-dose chemotherapy as consolidation: a non-cisplatin-based induction approach.
    Badreldin W; Krell J; Chowdhury S; Harland SJ; Mazhar D; Harding V; Frampton AE; Wilson P; Berney D; Stebbing J; Shamash J
    BJU Int; 2016 Mar; 117(3):418-23. PubMed ID: 25430674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer.
    Rick O; Bokemeyer C; Beyer J; Hartmann JT; Schwella N; Kingreen D; Neureither S; Metzner B; Casper J; Wandt H; Hartmann F; Schmoll HJ; Derigs G; Gerl A; Berdel WE; Kanz L; Siegert W
    J Clin Oncol; 2001 Jan; 19(1):81-8. PubMed ID: 11134198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term survival after high-dose salvage chemotherapy for germ cell malignancies with adverse prognostic variables.
    Vaena DA; Abonour R; Einhorn LH
    J Clin Oncol; 2003 Nov; 21(22):4100-4. PubMed ID: 14615439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
    Kleiner S; Kirsch A; Schwaner I; Kingreen D; Schwella N; Huhn D; Siegert W
    Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.